The Doctors Company Welcomes Two Renowned Medical Leaders to Its Board of Governors

In a significant move aimed at bolstering its leadership and enhancing service delivery, The Doctors Company, the largest physician-owned medical malpractice insurer in the United States, announced the appointment of Dr. Akhil Saklecha and Dr. Owen Garrick to its esteemed Board of Governors on May 26, 2026. This appointment is expected to leverage their extensive experience to improve medical malpractice insurance and services for physicians across the nation.

The Doctors Company's Board of Governors consists of a diverse group of leaders from various sectors, including medical professionals, healthcare innovators, and distinguished executives from leading healthcare systems, technology firms, and insurance companies. Richard E. Anderson, MD, the Chairman and CEO, expressed his excitement regarding the new appointments, stating, "Their combined expertise across medicine, healthcare innovation, clinical research, and executive leadership will strengthen our ability to deliver the best imaginable service to the clinicians and healthcare institutions we serve."

Meet the New Board Members

Dr. Akhil Saklecha

Dr. Saklecha brings over 30 years of experience in both emergency medicine and healthcare innovation. Currently serving as a Managing Director at WittKieffer's Global Investor-Backed Markets team, he works closely with boards, investors, and executive teams throughout the healthcare sector. His previous role as Chief Scientific Officer for Acute Care at Danaher saw him spearheading scientific and technological strategies across the diagnostics businesses. Dr. Saklecha’s expertise is further highlighted by his tenure as Managing Director of Cleveland Clinic Ventures, a role in which he supported the commercialization of innovative medical technologies. He is board-certified in emergency medicine and continues to practice on a part-time basis at the Cleveland Clinic.

Dr. Saklecha's educational accomplishments include a medical degree from Northeast Ohio Medical University and an MBA from the University of Tennessee Haslam College of Business, making him a remarkable addition to the board.

Dr. Owen Garrick

With a wealth of experience in clinical research, Dr. Garrick recently served as the Dean of Clinical Trials at the Mayo Clinic, leading initiatives aimed at extending the reach of clinical trials to more patients. His distinguished career includes senior leadership roles at prominent organizations like CVS Health, McKesson, Novartis, and Merck, where he was responsible for various aspects of clinical development and regulatory science. His expertise also extends to ethics and health system management.

Dr. Garrick's rich educational background features an AB in Psychology from Princeton University, an MD from Yale School of Medicine, and an MBA from the Wharton School at the University of Pennsylvania. His extensive knowledge in clinical trials and healthcare management positions him as a vital asset to The Doctors Company.

The Doctors Company’s Commitment

The Doctors Company has long been committed to advancing and protecting the practice of good medicine. As part of the TDC Group, this organization offers tailored guidance, resources, and coverage solutions for healthcare providers of all sizes across the healthcare landscape. With an advocacy program covering all 50 states, the company is uniquely positioned to help its clients navigate the complexities of today’s healthcare environment.

In addition to expanding its Board of Governors, The Doctors Company continues to engage with industry trends and data-driven insights. Stakeholders and healthcare professionals are encouraged to follow their activities through their social media channels including X (@doctorscompany), YouTube, LinkedIn, and Facebook.

Conclusion

With the appointment of Dr. Saklecha and Dr. Garrick, The Doctors Company is poised to enhance its leadership and continue its mission to provide unparalleled service and protection for medical professionals. The strategic insights and diverse experiences that these two new board members bring are expected to enrich the company’s direction and contribute significantly to its ongoing commitment to the healthcare community.